Epidermal growth factor receptor inhibitors in lung cancer: Smaller or larger molecules, selected or unselected populations?

Journal of Clinical Oncology

Volumn 23, Issue 36, 2005, Pages 9044-9047

  Hirsch, Fred R ^a   Bunn Jr , Paul A ^a  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; GEMCITABINE; NAVELBINE; PACLITAXEL; PEMETREXED; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE CONTROL; DRUG EFFICACY; DRUG SENSITIVITY; DRUG TOLERABILITY; EDITORIAL; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; PATIENT SELECTION; PRIORITY JOURNAL; TREATMENT OUTCOME; CHEMICAL STRUCTURE; DRUG ANTAGONISM; LUNG TUMOR; NOTE; PATHOPHYSIOLOGY;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; MOLECULAR STRUCTURE; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 33644822965     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.03.6129     Document Type: Editorial

References (17)

1. Shepherd FA, Rodrigues PJ, Ciuleanu T, et al: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123-132, 2005
2. Thatcher N, Chang A, Parikh P, et al: ISEL: A phase III survival study comparing gefitinib (IRESSA) plus best supportive care (BSC) with placebo plus BSC, in patients with advanced non-small-cell lung cancer (NSCLC) who had received one or two prior chemotherapy regimens. Lung Cancer 49:S4, 2005 (abstr Pr4)
3. Kim ES, Mauer AM, Tran HT, et al: A phase II study of cetuximab, an epidermal growth factor receptor (EGFR) blocking antibody, in combination with docetaxel in chemotherapy refractory/resistant patients with advanced non-small cell lung cancer: Final report. Proc Am Soc Clin Oncol 22:642s, 2003 (abstr 2581)
4. Rosell R, Daniel C, Ramlau R, et al: Randomized phase II study of cetuximab in combination with cisplatin (C) and vinorelbine (V) vs. CV alone in the first-line treatment of patients (pts) with epidermal growth factor receptor (EGFR)-expressing advanced non-small-cell lung cancer (NSCLC). J Clin Oncol 22:620, 2004 (suppl; abstr 7012)
5. Kelly K, Hanna N, Rosenberg A, et al: A multi-center phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small cell lung cancer. Proc Am Soc Clin Oncol 22:644s, 2003 (abstr 2592)
6. Robert F, Blumenstein G, Herbst R, et al: Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naïve advanced non-small-cell lung cancer. J Clin Oncol 23:9089-9096, 2005
7. Hanna N, Bonomi P, Lynch TJ, et al: A phase II trial of cetuximab as therapy for recurrent non-small cell lung cancer (NSCLC). Lung Cancer 49:S38, 2005 (abstr O-106)
8. Mukohara T, Engelman JA, Hanna NH, et al: Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. J Natl Cancer Inst 97:1185-1194, 2005
9. Albain KS, Green SJ, Ravdin PM, et al: Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent: Initial results from intergroup trial 0100 (SWOG-8814). Proc Am Soc Clin Oncol 21:37a, 2002 (abstr 143)
10. Bailey LR, Kris MG, Wolf M, et al: Tumor EGFR membrane staining is not clinically relevant for predicting response in patients receiving gefitinib ('Iressa', ZD1939) monotherapy for pretreated advanced non-small-cell lung cancer: IDEAL1 and 2. 94th Annual Meeting of the American Association for Cancer Research, Washington DC, 2003 (abstr LB-170), July 13, 2003
11. Cappuzzo F, Gregorc V, Rossi E, et al: Gefitinib in pretreated non-small-cell lung cancer (NSCLC): Analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC. J Clin Oncol 21:2658-2663, 2003
12. Parra HS, Cavina R, Latteri F, et al: Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer. Br J Cancer 91:208-212, 2004
13. Cappuzzo F, Hirsch FR, Rossi E, et al: Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 97:643-655, 2005
14. Tse C, Treaba DO, Goldstein LC, et al: Sensitivity of immunohistochemical detection of EGFR could impact patient eligibility for anti-EGFR therapy. J Clin Oncol 23:272, 2005 (suppl; abstr 3607)
15. Hirsch FR, Varella-Garcia M, McCoy J, et al: Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: A Southwest Oncology Group Study. J Clin Oncol 23:6838-6845, 2005
16. Tsao MS, Sakurada A, Cutz JC, et al: Erlotinib in lung cancer: Molecular and clinical predictors of outcome. N Engl J Med 353:133-144, 2005
17. Hirsch FR, McCoy J, Cappuzzo F, et al: FISH and immunohistochemistry can be used to select NSCLC patients, who will not benefit from gefitinib treatment. Lung Cancer 49:338, 2005 (abstr O-107)